MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
IEEE Spectrum
April 2013
Neil Savage
Path Found to a Combined MRI and CT Scanner Omni-tomography could add together the advantages of several medical imaging technologies mark for My Articles similar articles
Chemistry World
June 21, 2006
Katharine Sanderson
Peptide Agent Tracks Angiogenesis A molecular imaging agent that can track the progress of tumour growth is about to be trialled by GE Healthcare. mark for My Articles similar articles
The Motley Fool
August 31, 2010
Brian Orelli
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. mark for My Articles similar articles
The Motley Fool
December 3, 2010
Brian Orelli
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. mark for My Articles similar articles
Chemistry World
October 16, 2007
Ned Stafford
Germany's 900m Euro Molecular Imaging Drive Five German companies and the Federal Ministry of Education and Research are to spend almost a billion euros in an effort to strengthen the nation's international competitiveness in molecular imaging, which will require a large dose of nanotechnology research. mark for My Articles similar articles
The Motley Fool
November 30, 2010
Brian Orelli
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. mark for My Articles similar articles
Managed Care
January 2005
Maureen Glabman
Health Plans Strain To Contain Rapidly Rising Cost of Imaging PET, CT, MRI -- these and other imaging technologies are valuable but costly. Aetna, Cigna, and a few other plans lead in clamping down on unnecessary use. mark for My Articles similar articles
The Motley Fool
January 28, 2010
Brian Orelli
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. mark for My Articles similar articles
Chemistry World
March 2011
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations mark for My Articles similar articles
The Motley Fool
January 29, 2010
Brian Orelli
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. mark for My Articles similar articles
InternetNews
July 27, 2010
Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain. mark for My Articles similar articles
The Motley Fool
July 12, 2010
Ryan McBride
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. mark for My Articles similar articles
The Motley Fool
February 28, 2011
Brian Orelli
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. mark for My Articles similar articles
The Motley Fool
October 11, 2010
Travis Hoium
Alexza Shares Plunged: What You Need to Know Alexza Pharmaceuticals shares fell 52% today after the Food and Drug Administration did not clear the company's new drug, AZ-004. mark for My Articles similar articles
Chemistry World
July 2010
Meeting Mr NICE guy Bibiana Campos-Seijo meets the chief executive of the National Institute for Health and Clinical Excellence, Sir Andrew Dillon mark for My Articles similar articles
The Motley Fool
March 30, 2011
Sean Williams
China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps. mark for My Articles similar articles
The Motley Fool
September 2, 2010
Brian Orelli
Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases. mark for My Articles similar articles
The Motley Fool
February 16, 2010
Brian Orelli
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. mark for My Articles similar articles
BusinessWeek
March 4, 2010
Frederik Balfour
The Ka-Ching in China Luring Medical Giants GE, Siemens, and others are angling for a piece of the $125 billion Beijing plans to spend on health care. mark for My Articles similar articles
BusinessWeek
July 15, 2010
Lopatto & Matsuyama
The Race for Diagnostic Tests for Alzheimer's GE, Bayer, and Avid are vying to be first to market an early test for Alzheimer's. mark for My Articles similar articles
Bio-IT World
January 12, 2004
Michael A. Greeley
What You See Is What You Get Better image analysis, better business models. The transition from analog to digital will allow systems biology to reach its full potential. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2011
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. mark for My Articles similar articles
The Motley Fool
September 20, 2010
Brian Orelli
Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time. mark for My Articles similar articles
The Motley Fool
March 4, 2010
Brian Orelli
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. mark for My Articles similar articles
The Motley Fool
July 30, 2010
Anand Chokkavelu
5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better. mark for My Articles similar articles
The Motley Fool
May 11, 2010
Ryan McBride
Clinical Data Seeks to Challenge Lilly, Pfizer in Antidepressant Market The tiny drug developer has no problem going up against bigger rivals. mark for My Articles similar articles
Chemistry World
July 16, 2010
Matt Wilkinson
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. mark for My Articles similar articles
The Motley Fool
May 21, 2010
Brian Orelli
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. mark for My Articles similar articles
The Motley Fool
April 26, 2011
Brian Orelli
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants. mark for My Articles similar articles
The Motley Fool
December 21, 2010
Brian Orelli
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. mark for My Articles similar articles
BusinessWeek
May 27, 2010
Michelle Cortez
Karo Bio's Prescription: Cheaper Drug Approval A Swedish company seeks a lower-cost review for its cholesterol drug. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2010
William Looney
In Through the Out Door The end of anther year is an appropriate time to highlight the march of time and the transitions that accompany it in Europe and in China. mark for My Articles similar articles
BusinessWeek
August 26, 2010
Tom Randall
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. mark for My Articles similar articles
The Motley Fool
April 29, 2011
Brian Orelli
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. mark for My Articles similar articles
The Motley Fool
October 27, 2010
Ralph Casale
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. mark for My Articles similar articles
The Motley Fool
June 25, 2010
Brian Orelli
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. mark for My Articles similar articles
Chemistry World
November 2010
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? mark for My Articles similar articles
The Motley Fool
December 2, 2010
Brian Orelli
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying. mark for My Articles similar articles
The Motley Fool
July 28, 2010
Jordan DiPietro
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage mark for My Articles similar articles
Managed Care
June 2005
Quick Results, Not Self-Referrals, Fuel Increase in Imaging Tests The researchers say that if self-referral were an important driver of the number of imaging services, they would have seen an acceleration in the growth of imaging services from 2001 to 2003 to offset the reductions in physician income brought about by reductions in the conversion factor. mark for My Articles similar articles
The Motley Fool
January 8, 2010
Brian Orelli
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands. mark for My Articles similar articles
The Motley Fool
September 14, 2010
Brian Orelli
42% Drop? Really? Tell Us Something We Didn't Know. Arena Pharmaceuticals gets knocked down for no good reason. mark for My Articles similar articles
BusinessWeek
January 21, 2010
John Carey
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. mark for My Articles similar articles
The Motley Fool
March 3, 2011
Brian Orelli
3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year. mark for My Articles similar articles
The Motley Fool
July 30, 2010
Brian Orelli
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. mark for My Articles similar articles
The Motley Fool
January 25, 2010
Brian Orelli
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. mark for My Articles similar articles
Chemistry World
June 2011
Breaking through the barrier Getting drug molecules into the brain means crossing the defensive blood-brain barrier. Anthony King investigates how chemists are infiltrating the brain's fortress mark for My Articles similar articles
The Motley Fool
March 31, 2011
Brian Orelli
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. mark for My Articles similar articles
The Motley Fool
September 15, 2010
Brian Orelli
Drug Approved. Now Let's Sell This Baby! With ink still wet on its FDA approval, Savient continues its plan to find a buyer. mark for My Articles similar articles
The Motley Fool
March 16, 2011
Brian Orelli
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. mark for My Articles similar articles